ASCO 2022

More data needed: Are the results clinical meaningful?…

CDK4/6i switch: who benefits from switching the CDK4/6…

What are the cosenquences of the new OS data for CDK4/6…

Paradigm shift in breast cancer: Where do we use the…

How to determine progress of disease? How to proceed…

ADCs & CDK4/6i - paradigm shifts and therapy switches…

Determining HER2 receptor expression: How do we target…

What clincial value has statistical signifcance? How…

Additional administration of ribociclib improves PFS…

Smart chemotherapy improves PFS

No changes in clinical practice after new CDK4/6i-data

Disappoiting final OS data and its implications for our…

Endocrine therapy alone is important in treatment of…

SG is a new therapy option for HR+/HER2- MBC patients

New standard of care for HR+/Her2low patients

Improvment of PFS & OS with activated alteration…

Good therapeutic option in HR+ HER2- mBC after failure…

New agents for the clincial practice

Option for overcoming endocrine resistance?

Patritumab Deruxtecan: HER3-targeted ADC in HER3…

Revolution in the field of HR+ disease

Sacituzumab govitecan improves PCr in patients with…

Combi SERD + Palbo reduces proliferation better than…

First evidence on benefit of CDK4/6 inhibitors beyond…

New SoC for large subpopulation of breast cancer…

My ASCO22 highlights in metastatic breast cancer

T-DxD should be the new SoC for Her2low MBC patients

Combination of ctDNA and TKa assesment may improve…

ADC: future therapeutic option in advanced HR+/HER2 BC

Possible explanations of the negative study

Impressive and practice changing data of ADCs mark the…

Practice changing data

SG may be a good option for pre-treated HR+/Her2- pts

Breakthrough news with antibody drug conjugate

No effect for local treatment of metastasis

Discontiunation of trial is disappointing despite…

Benefit of CDK4/6 Switch after Progression

Palbociclib - Overall survival data

Oligometastasis: no advantage of additional…

Exciting advances across a wide subset of breast…

Exciting and practice changing news for HR+/Her2low MBC…

Fascinating data of ADCs in breast cancer at ASCO22

La valutazione combinata di ctDNA e TKa può aiutare a…

Les nouvelles données impressionnantes des ADC à l’ASCO…

I nuovi impressionanti risultati degli ADC a l’ASCO…

SG come nuova opzione di cura per le pazienti con…

Pierwsze dane nt. skuteczności inhibitorów CDK4/6 po…

Novità entusiasmanti e practice changing per le…

Nowy standard dla znaczącej subopulacji chorych na raka…

PALOMA2 e MAINTAIN: cosa cambia nella pratica clinica?

Il sacituzumab govitecan migliora il PFS nei tumori…

Noutăți inovatoare cu conjugatul de medicamente cu…

ADCs en cáncer de mama con receptores hormonales…

Adding towards deescalation in luminal A EBC by…

CT benefit for elderly patients, if they are able to…

Ovarian function suppression - it is here to stay!

Neoadjuvant Pembro decreased RCB. SG - first promising…

Combi SERD + Palbo redzuert proliferation better than…

My ASCO22 highlights in early breast cancer

Molecular landscape - Part 1

Immunotherapy - Part 1

Molecular landscape - Part 2

New treatment options for METexon 14 skipping:…

COSMIC-021: Not practice-changing, but interesting…

New components and therapies for advanced NSCLC

Strategies for PD-L1 > 50%

Promising results for pre-treated patients with…

In the second line: Options for Immunotherapy…

PD-L1 over 50%: Chemo-IO or IO?

Bispecific Antibodies - the cMET field is moving

Options after progression to chemo/IO and for KRASG12C…

Role of IO and chemo-IO in patients with PD-L1 > 50%

A chemo-free option in patients with EGFR-mutation

KRASG12C mutation: Adagrasib is comparabale to…

Amivantamab as a future option for METex14 patients?

Multiple aquired resistance mutations may drive disease…

Is adagrasib an alternative to sotorasib?

CLN-081 for patients with metastatic NSCLC and an…

New option in patients harboring METex14 mutation

Die Rolle von IO und Chemo-IO bei Patienten mit PD-L1 >…

CLN-081 voor patienten met gemetastaseerd NSCLC en een…

PD-L1 über 50 % - was tun?

COSMIC-021: Nicht praxisverändernd, aber interessante…

Nuevas terapias para el CPCNP avanzado

Bispezifische Antikörper - Neues von CHRYSALIS

Veelbelovende resultaten voor voorbehandelde patienten…

Une nouvelle option, l’amivantamab, en situation de…

Nieuwe behandelopties voor METexon 14 skipping:…

Segunda Linea: opciones tras resistencia a…

Was tun nach Versagen einer Chemoimmun-Therapie?

Neoadjuvant and adjuvant therapy - Part 2

CheckMate-816: Neoadjuvant therapy

NADIM-II strengthens the findings from CheckMate-816

A new option in neoadjuvant chemoimmunotherapy

New treatment approaches in Stage III

Neue Ansätze im Stadium III

Immuncheckpoint-inhibitor therapy

SCLC-Update: No benefit with Tiragolumab/Chemo-IO is…

SKYSCRAPER-02: Subgroups could be important

mHSPC: Transatlantic differences in genetic testing &…

mCRPC: LuPSMA - new treatment option in mCRPC

Phase 1 study on combining LuPSMA treatment with…

ADT alone is no longer standard of care

Ongoing trial invetiagting the impact of…

The efficacy of doublets in mHSPC

Surrogate endpoints in mHSPC

Frequent imaging for early detection of metastases in…

Lu-PSMA effective regardless of prior or concomitant…

SHR3680 - do we need a new androgen receptor inhibitor

LuPSMA & cabazitaxel are better than SoC alone

3 year overall survival of TheraP study

The highlights in GU cancers of ASCO22

Arbiraterone + Olaparib: Is it synergistic?

Lu-PSMA in the third line

TheraP shows no difference in overall survival between…

Further updates from the VISION trial

GGT impacts PCa patients care

SUV mean at PET images as a prognostic tool for PSMA…

SUVmean is highly predictive of better PFS and OS

Value of triple-therapy - complimentary study to…

PFS good surrogate endpoint for overall survival

Tidigare endpoints I mHSPC studier

Treårs överlevnadsresultat i TheraP studien.

Pas de nouvelles sensationnelles mais des données…

Kombination av 177-LU-PSMA-617 och pembrolizumab I Fas…

Kvantifiering av PMSA PET upptaget som prognostisk…

What are the consequences for future trial design?

EVEREST: Inisghts from the negative trial

The relevance of quality of life in kidney cancer!

Importance of health related quality of life

Combi Axi + Pembro also successful with good risk…

Should Everolimus be revisited for high-risk patients?

PSMA-PET may improve imaging of clear cell RCC

Belzutifann shows good tumor activity in renal cancer

QoL & DepOR correlate with clinical outcomes - reminder…

The highlights in GU cancers of ASCO22

Depth of remission in firstline

Clear evidence for durable benefit for patients with…

Pas de nouvelles sensationnelles mais des données…

The role of systemic treatment in the pre-operative…

New data on TKi utilization in bladder cancer

The end of of VEGF-targeted therapy in urothelial…

ADCs: News from ASCO 2022

No big scoop, but encouraging results

My highlights of metastasized urothelial cancer

Exciting future for ADCs

The highlights in GU cancers of ASCO22

Investigating sasanlimab in BCG-unresponsive NMIBC

Perioperative immuno-chemotherapy in MIBC

My highlights in localized urothelial cancer

BCG failure

Σημαντικά μηνύματα για τον ουροθηλιακό καρκίνο από το…

Radiotherapy as a new standard for cisplatin ineligible…

Opportunities & challenges of cancer genetics

Systemic therapy

News from Sarcoma

Few testicular tumors after 5 years